Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization
| Autor: | Leandro Maranan, John A. Sorenson, Richard F. Spaide |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty Intraocular pressure Visual acuity Triamcinolone acetonide Porphyrins genetic structures Anti-Inflammatory Agents Visual Acuity Pilot Projects Triamcinolone Acetonide Injections Macular Degeneration Endophthalmitis Ophthalmology medicine Humans Prospective Studies Fluorescein Angiography Aged Aged 80 and over Photosensitizing Agents business.industry Verteporfin Macular degeneration medicine.disease Acetonide eye diseases Choroidal Neovascularization Surgery Vitreous Body Choroidal neovascularization Treatment Outcome Photochemotherapy Drug Therapy Combination Female medicine.symptom business medicine.drug |
| Zdroj: | Ophthalmology. 110(8) |
| ISSN: | 0161-6420 |
| Popis: | Purpose To examine combined photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Design Noncomparative case series. Participants Twenty-six eyes of 26 patients with CNV secondary to AMD. Thirteen with CNV, without restriction to type, were not treated with prior PDT and were called the Newly Treated group. Thirteen patients with prior PDT therapy who experienced visual loss during treatment with PDT alone comprised the remainder and were termed the Prior PDT group. Methods Patients with CNV were treated with PDT immediately followed by an intravitreal injection of 4 mg of triamcinolone acetonide. Visual acuity was measured by Early Treatment Diabetic Retinopathy Study protocol refraction. Need for retreatment was based on fluorescein angiographic evidence of leakage at 3-month follow-up intervals. Main outcome measures Visual acuity and retreatment rate. Results Of the 13 patients in the Newly Treated group the mean visual acuity change at 3 months was an improvement of 1.9 lines, and 4 (30.8%) had an improvement of at least 3 lines. Two patients (15.4%) required retreatment at 3 months. At the 6-month follow-up, available for 12 patients in the Newly Treated group, the mean visual acuity change from baseline was an improvement of 2.4 lines, 4 patients (33%) had an improvement of at least 3 lines and 1 patient required retreatment. At both time points the visual acuity was significantly greater than at baseline ( P = 0.023 and P = 0.007, at the 3-month and 6-month time points, Wilcoxon signed ranks test) for patients in the Newly Treated group. Among the 13 patients in the Prior PDT group, the mean change in visual acuity from baseline at the 3-month follow-up was 0.31 lines and 1 patient (7.7%) had an improvement of at least 3 lines. Six-month follow-up was available for 11 patients in the Prior PDT group and the mean change from baseline visual acuity was 0.1 lines and 1 patient (9.1%) experienced an improvement of 3 or more lines. No patient in the Prior PDT group required retreatment at 3 or 6 months. At the 3-month and 6-month time points the visual acuity was not significantly different than the baseline acuity in the Prior PDT group. No patient in either group at any time point experienced a loss of visual acuity of 3 or more lines. Five patients (19.2%), 3 in the Newly Treated group and 2 in the Prior PDT group, required monodrop therapy to control their intraocular pressure. No patient developed endophthalmitis. Conclusion Although the number of patients in this pilot study was limited, the improvement of acuity and the lack of fluorescein leakage in these patients suggest combination therapy with PDT and intravitreal triamcinolone acetonide, particularly when used as first-line therapy, merits further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|